La bourse est fermée

Merck KGaA (MRK.DE)

XETRA - XETRA Prix différé. Devise en EUR
Ajouter à la liste dynamique
163,60+3,40 (+2,12 %)
À la clôture : 05:35PM CET

Merck KGaA

Frankfurter Strasse 250
Darmstadt 64293
Germany
49 6151 72 0
https://www.emdgroup.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers - Specialty & Generic
Employés à temps plein62 908

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Ms. Belen Garijo Lopez M.D.Chair of Executive Board & CEO6,62MS.O.1960
Ms. Helene von RoederCFO & Member of Executive Board1,23MS.O.1970
Dr. Kai BeckmannCEO of Electronics & Member of the Executive Board4,85MS.O.1965
Mr. Peter GuenterCEO of Healthcare Business & Member of Executive Board5,58MS.O.1962
Dr. Matthias J. HeinzelCEO of Life Science Sector & Member of Executive Board5,22MS.O.1967
Ms. Barbara WeilandChief Compliance OfficerS.O.S.O.1974
Mr. Dietmar EidensHead of the Global HR Business Partner OrganizationS.O.S.O.1958
Mr. Frank GotthardtHead of Corporate & Government Relations - EuropeS.O.S.O.S.O.
Mr. Marc HornHead of Life Science ControllingS.O.S.O.1975
Dr. Michael HeckmeierHead of the Display Materials Business Unit for Performance MaterialsS.O.S.O.1967
Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Merck KGaA en date du 1 mars 2024 est 5. Les scores principaux sont Audit : 5; Société : 6; Droits des actionnaires : 10; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.